BPC-157 works locally — injected near the injury or taken orally for gut. TB-500 (Thymosin β4) works systemically, accelerating cell migration and angiogenesis throughout the whole body. Together they cover every angle of tissue repair: local repair stimulus from BPC-157, systemic mobilization from TB-500. This pairing is the most documented healing stack in the research literature and the starting point for most recovery protocols.
BPC-157: 250–500 mcg/day subcutaneous, injected near injury site
TB-500: 2 mg twice per week, subcutaneous
Inject both compounds on the same days (e.g., Monday and Thursday for TB-500)
Cycle length: 4–8 weeks
Break: 2–4 weeks before next cycle
Clinical References
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011.
DOI: 10.1152/japplphysiol.00945.2010 ↗Sikiric P, Seiwerth S, Rucman R, et al. "Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157." Curr Med Chem. 2012.
DOI: 10.2174/092986712799320732 ↗Goldstein AL, Hannappel E, Sosne G, Kleinman HK. "Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications." Expert Opin Biol Ther. 2012.
DOI: 10.1517/14712598.2012.663154 ↗Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004.
DOI: 10.1038/nature02859 ↗Compound Profile
2-compound stack · Beginner Friendly
GPCR agonist · local tissue repair & gut cytoprotection
Actin-binding protein · systemic cell migration & angiogenesis
Combined Benefits
CJC-1295 (a GHRH analog) tells your pituitary to prepare a GH release. Ipamorelin (a selective ghrelin receptor agonist) triggers the actual GH pulse — but cleanly, without the cortisol and prolactin spikes caused by GHRP-2 or GHRP-6. CJC-1295 DAC extends the window of pituitary priming through its Drug Affinity Complex modification, while Ipamorelin pulses within that window. Inject both together before sleep to amplify the body's natural GH surge during deep sleep.
CJC-1295 DAC: 1–2 mg per week, subcutaneous
Ipamorelin: 200–300 mcg before sleep, subcutaneous
Inject both simultaneously before bed on an empty stomach (no food 2h prior)
Run 12–16 week cycles, then 4–8 week break
Clinical References
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." J Clin Endocrinol Metab. 2006.
DOI: 10.1210/jc.2005-1536 ↗Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998.
DOI: 10.1530/eje.0.1390552 ↗Bowers CY. "Unnatural growth hormone-releasing peptide begets natural ghrelin." J Clin Endocrinol Metab. 2001.
DOI: 10.1210/jcem.86.4.7528 ↗Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues." Sex Med Rev. 2018.
DOI: 10.1016/j.sxmr.2017.02.004 ↗Compound Profile
2-compound stack · Intermediate
Pituitary stimulation · sustained GH secretion (DAC modified)
Selective ghrelin receptor agonist · clean GH pulse
Combined Benefits
Epithalon (Epitalon) is a synthetic tetrapeptide derived from the pineal gland extract Epithalamin. Multiple peer-reviewed studies by Khavinson et al. demonstrate its ability to activate telomerase — the enzyme that rebuilds telomere length in somatic cells. GHK-Cu (copper tripeptide) drives collagen and glycosaminoglycan synthesis, activates antioxidant pathways, and has been shown to regulate over 4,000 human genes toward a state associated with tissue regeneration. Together they address aging at both the cellular clock level and the structural tissue level.
Epithalon: 5–10 mg daily for 10–20 consecutive days, 1–2 cycles per year
GHK-Cu: 1–2 mg subcutaneous 3× per week, or topical application twice daily
Schedule Epithalon cycles in spring and fall (circannual rhythm)
GHK-Cu can be run continuously — no cycling required
Clinical References
Khavinson VKh, Bondarev IE, Butyugov AA. "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." Bull Exp Biol Med. 2003.
PubMed: 12937774 ↗Anisimov VN, Khavinson VKh, Provinciali M, et al. "Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice." Int J Cancer. 2002.
DOI: 10.1002/ijc.10362 ↗Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." Int J Mol Sci. 2019.
DOI: 10.3390/ijms20071570 ↗Pickart L, Vasquez-Soltero JM, Margolina A. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." Biomed Res Int. 2015.
DOI: 10.1155/2015/648108 ↗Compound Profile
2-compound stack · Intermediate
Telomerase activator · telomere elongation in somatic cells
Collagen & elastin synthesis · 4,000+ gene regulation
Combined Benefits
Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin. It modulates GABA-A receptor expression, increases BDNF and enkephalins, and produces anxiolytic effects without the sedation, tolerance, or withdrawal risk of benzodiazepines. Semax is an ACTH4-7 analog that dramatically upregulates BDNF, NGF, and VEGF expression in the hippocampus and prefrontal cortex. Protocol: Selank in the morning for baseline calm and working memory support. Semax before concentrated work for focus, recall speed, and problem-solving. They work through different mechanisms — no redundancy, genuine complementarity.
Selank: 250–500 mcg per nostril (500–1000 mcg total), intranasal, morning
Semax: 200–600 mcg per nostril, intranasal, 30 min before focused work sessions
Both can be used as-needed or daily — short-term use requires no cycling
For daily use, consider 5 days on / 2 days off to maintain receptor sensitivity
Clinical References
Semenova TP, Kozlovskaya MM, Zuikov AV, Kozlovskii II. "Effect of selank on cognitive processes in rats after damage of the serotoninergic system." Bull Exp Biol Med. 2009.
PubMed: 19856029 ↗Dolotov OV, Karpenko EA, Inozemtseva LS, et al. "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." Brain Res. 2006.
DOI: 10.1016/j.brainres.2006.04.108 ↗Zozulya AA, Kost NV, Sokolov OYu, et al. "Selank and short tuftsin peptides' effect on opioid peptide degradation and their anxiolytic activity." Peptides. 2001.
DOI: 10.1016/S0196-9781(01)00411-4 ↗Gusev EI, Skvortsova VI, Zhuravleva EYu, Vanichkin AV. "Neuroprotective effects of Semax in patients with cerebral ischemic stroke." Cerebrovasc Dis. 1996.
Compound Profile
2-compound stack · Beginner Friendly
GABA-A modulator · anxiolytic, BDNF & enkephalin elevation
BDNF / NGF / VEGF upregulation · hippocampal neurotrophy
Combined Benefits
Semaglutide (Ozempic/Wegovy) is the most effective weight-loss compound ever approved by the FDA. The STEP 1 trial (NEJM, 2021) showed an average 14.9% body weight reduction at 68 weeks in non-diabetic adults — unprecedented for a pharmacological intervention. The common side effect: rapid fat loss accelerates skin laxity, particularly in the face and mid-body. GHK-Cu paired topically addresses this directly — it activates fibroblasts, increases collagen and elastin synthesis, and has been shown to tighten skin structure. This combination captures the full benefit of GLP-1 weight loss while actively protecting tissue quality during the cut.
Semaglutide: start 0.25 mg/week × 4 weeks, then titrate to 0.5 mg → 1 mg → 2 mg as tolerated
GHK-Cu: topical 2× daily on face and body areas of concern, beginning at week 1
GHK-Cu subcutaneous 1 mg 3× weekly optional for systemic collagen support
Inject semaglutide on the same day each week, rotate injection sites
Monitor: weight, HbA1c, heart rate — taper semaglutide dose if side effects persist
Clinical References
Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021.
DOI: 10.1056/NEJMoa2032183 ↗Davies M, Færch L, Jeppesen OK, et al. "Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, placebo-controlled, phase 3 trial." Lancet. 2021.
DOI: 10.1016/S0140-6736(21)00921-5 ↗Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." Biomedicines. 2018.
DOI: 10.3390/biomedicines6020077 ↗Murad S, Grove D, Lindberg KA, Reynolds G, Sivarajah A, Pinnell SR. "Regulation of collagen synthesis by ascorbic acid." Proc Natl Acad Sci USA. 1981.
DOI: 10.1073/pnas.78.5.2879 ↗Compound Profile
2-compound stack · Advanced — requires MD
GLP-1 receptor agonist · appetite suppression & insulin secretion
Collagen & elastin synthesis · 4,000+ gene regulation
Combined Benefits
Go Deeper
Named combinations with mechanism breakdowns — why specific compounds pair together and what each blend targets.
Six aging mechanisms with compound breakdowns, clinical references, and protocol write-ups for each pillar.
Every compound across every stack — individual entries with FDA status, half-life, dosing tables, and side effects.